Posts tagged: ochre bio

Brian Gormley ⁦of The Wall Street Journal has featured Ochre Bio and their novel approach to tackling chronic liver disease (a top ten cause of death globally).

“We’re starting with a focus on improving outcomes for transplant patients, and are making exciting progress scientifically here in Oxford. With great investors onboard, a wonderful team coming together, and an international network of transplant / clinical partners – we are well on our way to developing life-saving medicines for one of the toughest healthcare challenges of our time” said Ochre Bio.

This article showcases Startup Pill’s top picks for the best Therapeutics startups. These startups are taking a variety of approaches to innovating inside of the Therapeutics industry and around the world. They are all exceptional startups well worth a follow.

We tried to pick companies across the size spectrum from cutting edge startups to established brands.

We selected these startups for exceptional performance in one of these categories:

• Innovation
  • Innovative ideas
  • Innovative route to market
  • Innovative product
• Growth
  • Exceptional growth
  • Exceptional growth strategy
• Management
• Societal impact

The goal of the 2021 Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation is to source innovative solutions to improve outcomes and experiences for all those affected by transplantation.

The Innovation Challenge will take place virtually in May 2021 and is currently accepting applications through February 19, 2021. Patient entrepreneurs – those who have been affected by chronic disease as either a patient or support partner for a loved one and started a company to develop solutions to an unmet need identified in their disease journey – are encouraged to apply.

Selected finalists will receive an invitation to pitch their company’s solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders. One winner will be awarded a $25,000 monetary grant. Competing finalists may be considered for possible partnerships or investments beyond the challenge. Beyond presenting their innovative ventures, the finalists will have the opportunity to exchange ideas on how to further advance patient innovation in the transplant community; engage with Lyfebulb founders, CSL Behring leadership leadership, representatives from the patient community, key opinion leaders and potential investors; and share insights with each other.

The Lyfebulb-CSL Behring Innovation Challenge stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on the issues encountered due to their personal experiences with a chronic illness (through their own diagnosis or that of a loved one).

Y Combinator’s Demo Day was a bit different this time around.

As concerns grew over the spread of COVID-19, Y Combinator shifted the event format away from the two-day gathering in San Francisco we’ve gotten used to, instead opting to have its entire class debut to invited investors and media via YC’s Demo Day website.

In a bit of a surprise twist, YC also moved Demo Day forward one week citing accelerated pacing from investors. Alas, this meant switching up its plan for each company to have a recorded pitch on the Demo Day website; instead, each company pitched via slides, a few paragraphs outlining what they’re doing and the traction they’re seeing, and team bios. It’s unclear so far how this new format — in combination with the rapidly evolving investment climate — will impact this class.

As we do with each class, we’ve collected our notes on each company based on information gathered from their pitches, websites and, in some cases, our earlier coverage of them.

To make things a bit easier to read, we’ve split things up by category rather than have it be one huge wall of text. These are the healthcare, biotech, fintech and nonprofit companies. You can find the other categories (such as B2B, consumer and robotics) here.

See which companies the TechCrunch staff liked the most over on Extra Crunch.